Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% below its 3-year average of 35.71%, near the low end of its 3-year range (0.00%–100.00%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
30.77%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.44%
median of 735 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Artiva Biotherapeutics, Inc.
Market Cap
$356.65M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
30.77%
5Y Avg
N/A
Market Cap
$356.40M
Gross Margin
93.73%
TTM Avg
92.44%
3Y Avg
93.34%
5Y Avg
78.89%
Market Cap
$353.98M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$353.31M
Gross Margin
98.15%
TTM Avg
96.49%
3Y Avg
98.25%
5Y Avg
98.83%
Market Cap
$350.90M
Gross Margin
99.32%
TTM Avg
95.85%
3Y Avg
93.96%
5Y Avg
99.79%
Market Cap
$365.35M
Gross Margin
99.87%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
83.33%
Market Cap
$373.86M
Gross Margin
25.47%
TTM Avg
27.02%
3Y Avg
15.55%
5Y Avg
5.84%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | $356.65M | 0.00% | 0.00% | 30.77% | N/A |
| Embecta Corp. (EMBC)vs › | $356.56M | 59.89% | 63.90% | 65.83% | 67.05% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $356.40M | 93.73% | 92.44% | 93.34% | 78.89% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $353.98M | 0.00% | 0.00% | 0.00% | 0.00% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.31M | 98.15% | 96.49% | 98.25% | 98.83% |
| Ocugen, Inc. (OCGN)vs › | $359.46M | 45.86% | 48.66% | 71.42% | -2398.51% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $350.90M | 99.32% | 95.85% | 93.96% | 99.79% |
| Opus Genetics, Inc. (IRD)vs › | $365.35M | 99.87% | 100.00% | 100.00% | 83.33% |
| Canopy Growth Corporation (CGC)vs › | $373.86M | 25.47% | 27.02% | 15.55% | 5.84% |
| Agenus Inc. (AGEN)vs › | $333.56M | 29.63% | -10.58% | -43.61% | -33.41% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 100.00% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | 100.00% |
